EDIT - Editas Expands Its Celgene Partnership After Another Strong Quarter
Editas Medicine (NASDAQ: EDIT) released third-quarter 2019 results on Tuesday morning. At first glance, its revenue and earnings numbers appeared to detail a terrible quarter, notably with a steep decline in revenue and widening generally accepted accounting principles (GAAP) losses. As evidenced by the stock's 9.5% pop yesterday, however, there's more to the genome-editing specialist's latest quarterly update in these early stages of its long-term story than its top and bottom lines seem to imply.
Before we get there, let's have a look at how those headline numbers fared relative to the same year-ago period:
Q3 2019